fetching data ...

AB0756 (2020)
GUSELKUMAB IMPROVED WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL
J. Curtis1, I. Mcinnes2, P. Rahman3, W. Tillett4, P. J. Mease5, A. Kollmeier6, E. C. Hsia6,7, B. Zhou6, P. Agarwal6, S. Peterson8, C. Han6
1Univ Alabama, Birmingham, United States of America
2Institute of Infection, Immunity & Inflammation, Univ Glasgow, Glasgow, United Kingdom
3Memorial Univ of Newfoundland, St Johns, Canada
4Royal Natl Hospital for Rheumatic Diseases, Bath, United Kingdom
5Swed Medical Ctr/Providence St. Joseph Health and U Wash School of Med, Seattle, United States of America
6Janssen Research & Development, LLC, Spring House, United States of America
7U Penn Med Ctr, Philadelphia, United States of America
8Janssen Global Svcs, LLC, Horsham, United States of America

Background: DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific mAb guselkumab (GUS) in psoriatic arthritis (PsA) pts, who experience impaired physical function, resulting in disability, work productivity loss, and economic consequences. 1


Objectives: To evaluate the effect of GUS on impaired work productivity and daily activity in DISC 2 using the Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI-PsA).


Methods: Bio-naïve adults with active PsA despite nonbiologic DMARDs &/or NSAIDs received subcutaneous GUS 100 mg every (q) 4 weeks (W); GUS 100 mg W0, W4, q8W; or placebo (PBO). WPAI-PsA assesses, due to PsA over the previous week, work time missed (absenteeism), impairment while working (presenteeism), and impaired overall work productivity (absenteeism + presenteeism) and daily activity. Percentage change from baseline was analyzed for WPAI-PsA domains using mixed-effect model repeated measure (MMRM). Indirect savings from improved overall work productivity were estimated with 2018 US mean yearly wage estimate (all occupations). 2


Results: At Week 24, impaired overall work productivity and daily activity were improved 20-22% in GUS-treated and 10-11% in PBO-treated pts (Table). Potential yearly indirect savings from improved overall work productivity was $10,242 with GUS q8W and $10,404 with GUS q4W vs $5,648 with PBO; $4,594 and $4,756 difference, respectively.


Conclusion: Improvement in overall work productivity and daily activity was greater with GUS versus PBO among pts with moderate-to-severe PsA, resulting in potential annual incremental economic gains.


REFERENCES:

[1]Tillett W et al. Rheumatol (Oxford). 2012;51:275–283.

[2]US Bureau of Labor Statistics. May 2018 National Occupational Employment and Wage Estimates United States. https://www.bls.gov/oes/current/oes_nat.htm#00-000

Model-based estimates of mean change from baseline in WPAI-PsA domains

% change from baseline PBO GUS 100 mg q8W GUS 100 mg q4W
W16 W24 W16 W24 W16 W24
Work time missed (absenteeism), n 155 152 141 145 145 143
LSMean -4.6 (-7.2, -1.9) -3.5 (-6.4, -0.6) -3.5 (-6.2, -0.7) -3.1 (-6.1, -0.1) -4.7 (-7.4, -2.0) -3.8 (-6.8, -0.8)
LSMean diff 1.1 (-2.6, -4.8)* 0.4 (-3.7, 4.5)* -0.2 (-3.9, 3.5)* -0.3 (-4.4, 3.8)*
Impairment while working (presenteeism), n 131 130 125 129 133 130
LSMean -10.3 (-13.9, -6.7) -10.2 (-13.7, -6.7) -16.1 (-19.7, -12.4) -19.4 (-22.9, -15.9) -15.1 (-18.7, -11.5) -19.5 (-23.0, -16.0)
LSMean diff -5.8 (-10.8, -0.8)† -9.2 (-14.0, -4.4) ‡ -4.8 (-9.7, 0.1)* -9.3 (-14.1, -4.5) ‡
Overall work productivity impairment (absenteeism + presenteeism), n 131 130 125 129 133 130
LSMean -11.2 (-15.0, -7.5) -10.9 (-14.6, -7.1) -15.9 (-19.7, -12.2) -19.7 (-23.4, -16.0) -15.8 (-19.5, -12.1) -20.0 (-23.7, -16.3)
LSMean diff -4.7 (-9.9, 0.5)* -8.8 (-14.0, -3.7) ‡ -4.6 (-9.7, 0.5)* -9.2 (-14.3, -4.0) ‡
Daily activity impairment, n 244 244 247 246 243 245
LSMean -10.6 (-13.3, -7.9) -10.3 (-13.1, -7.6) -17.1 (-19.8, -14.4) -21.5 (-24.2, -18.7) -17.0 (-19.7, -14.3) -20.5 (-23.2, -17.7)
LSMean diff -6.5 (-10.2, -2.8) ‡ -11.1 (-15.0, -7.4) ‡ -6.5 (-10.2, -2.7) ‡ -10.2 (-14.0, -6.4) ‡

Data are % (95% CI)

*p>0.05, †p<0.05, ‡ p<0.001

LSmeans, p values based on MMRM

LSmean diffs, p values vs PBO


Acknowledgments: None


Disclosure of Interests: Jeffrey Curtis Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Proton Rahman Grant/research support from: Janssen and Novartis, Consultant of: Abbott, AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Novartis, and Pfizer., Speakers bureau: Abbott, AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Novartis, Pfizer, William Tillett Grant/research support from: AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, MSD, Pfizer Inc, UCB, Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer Inc, UCB, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Elizabeth C Hsia Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Bei Zhou Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Prasheen Agarwal Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Steve Peterson Employee of: Janssen Research & Development, LLC, Chenglong Han Employee of: Janssen Research & Development, LLC

Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1671
Session: Psoriatic arthritis (Abstracts Accepted for Publication)